Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-12-2023 | Citalopram | Case report

Atorvastatin/citalopram

Muscle pain due to pharmacokinetic drug-drug interaction: case report

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:Drug interaction
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Petrykiv S, et al. Better to avoid fluvoxamine in patients at risk of myopathy. Risk of clinically relevant interactions of SSRIs + statins. [Dutch]. Pharmaceutisch Weekblad 158: 32-35, No. 10, 10 Mar 2023. Available from: URL: http://www.pw.nl/archief [Dutch; summarised from a translation] Petrykiv S, et al. Better to avoid fluvoxamine in patients at risk of myopathy. Risk of clinically relevant interactions of SSRIs + statins. [Dutch]. Pharmaceutisch Weekblad 158: 32-35, No. 10, 10 Mar 2023. Available from: URL: http://​www.​pw.​nl/​archief [Dutch; summarised from a translation]
Metadata
Title
Atorvastatin/citalopram
Muscle pain due to pharmacokinetic drug-drug interaction: case report
Publication date
01-12-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51383-1

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Levodopa

Case report

Ocrelizumab

Case report

Teclistamab